Axial Spondyloarthritis Axspa Market

DelveInsight’s ‘Axial Spondyloarthritis (axSpA)- Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the axSpA, historical, and forecasted epidemiology as well as the axSpA market trends in the United States


The axSpA market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted United States axSpA market size from 2018 to 2030. The Report also covers current axSpA treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States

Study Period: 2018–2030

Axial Spondyloarthritis (axSpA) Disease Understanding and Treatment Algorithm

Axial Spondyloarthritis (axSpA) Overview

Axial spondyloarthritis (axSpA) is a chronic, immune-mediated, inflammatory condition that consists of two subsets, which clinically have been defined as ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Nr-axSpA is characterized by the absence of definitive x-ray evidence of structural damage to the sacroiliac (SI) joint by plain x-ray. Since the SI joint x-ray interpretation is subjective, the distinction between nr-axSpA and AS is not absolute. Sacroiliitis (inflammation of the SI joint) and inflammation of the spine are predominant features of axSpA; hence patients typically present with inflammatory back pain. Other manifestations, such as enthesitis, dactylitis, peripheral arthritis, anterior uveitis, psoriasis, and inflammatory bowel disease, are common. Over time many patients with nr-axSpA develop the structural damage of sacroiliac joints, ultimately progressing to AS; however, some nr-axSpA patients will never advance to this stage. The clinical manifestations for axSpA and nr-axSpA are similar to the patients’ disease burden experience.


Patients with axSpA commonly complain of back pain that starts before 45 years of age. Back pain’s characteristic features include chronicity (>3 months), insidious onset, improvement with exercise, an occurrence at night with improvement upon waking, and no rest. Inflammatory back pain (IBP) criteria are essential in screening for axSpA. Among at-risk patients, the sensitivity of IBP (approximately 70–95%) for axSpA is relatively high (back pain >3 months with onset age)

Continued in the report…..


Axial Spondyloarthritis (axSpA) Diagnosis

The diagnosis of axSpA is based upon a combination of symptoms, physical examination, blood tests, and imaging tests such as X-ray and magnetic resonance imaging (MRI). Based on the results, a clinician can assign a degree of probability to whether axSpA is causing the symptoms. The diagnosis cannot be made by ticking a checklist. In general, axSpA should be considered if the patients have daily back pain for more than 3 months that starts before 45, especially if this back pain is predominantly present in the morning and wakes the patient up at night and improves after movement.


There are no blood tests that, by themselves, can definitively diagnose or exclude axSpA. However, testing for the presence of one particular type of the human leukocyte antigen (HLA) gene, HLA-B27, can be helpful in certain people. AxSpA is less likely in a person with a negative test for HLA, tests for proteins called “acute phase reactants” are sometimes helpful but are not diagnostic for axSpA; these tests, which are markers of inflammation in the body, include C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) tests.


Patients with axSpA develop characteristic changes in the sacroiliac joints. These are the joints that connect the base of the spine (sacrum) to the large pelvic bone (ilium) on both sides. In ankylosing spondylitis (AS), these changes can be seen on radiograph (X-ray) images.


Imaging tests such as MRI detect the disease earlier than plain X-rays. In nr-axSpA, findings suggesting inflammation in the sacroiliac joints may be present on MRI when the X-rays are negative. The interpretation of X-ray and the MRI requires training and is observer-dependent, to a certain extent. Clinicians might not agree on the same X-ray or MRI. MRI changes suggestive of SpA can sometimes be seen even in healthy people. Imaging tests should always be interpreted in the context of the symptoms, physical examination, and blood tests.

Continued in the report…..


Axial Spondyloarthritis (axSpA) Treatment

Optimal treatment of axial spondyloarthritis (axSpA) requires a combination of non-pharmacological and pharmacological treatments. Non-pharmacological strategies involve mainly exercise therapies, education, lifestyle and behavioral changes, and self-management. The currently licensed drug treatments for axSpA are NSAIDs and biologic DMARDs (bDMARDs) targeting TNF or IL-17A, which in general appear to have similar clinical efficacy in AS and non-radiographic AxSpA. Treatment for axSpA usually starts with nonsteroidal anti-inflammatory drugs (NSAIDs), Non-steroidal anti-inflammatory drugs (NSAIDs) are highly effective against the major symptoms of axSpA (pain and stiffness) and may have disease-modifying properties including retarding progression of structural damage in the spine. Therefore, NSAIDs, unless contraindicated, are the treatment of choice for the majority of patients with axSpA. Beyond NSAIDs, only tumor necrosis factor (TNF) α blockers are effective and approved for the treatment of active axSpA. Medicines like naproxyn (Naprosyn) or indomethacin (Indocin), can relieve pain and inflammation.


All medicines have side-effects, including NSAIDs. Risk increases with higher doses and longer use. High doses are usually needed to control symptoms of axSpA. Acetaminophen (Tylenol) may be used to reduce pain if the patient is not able to take NSAIDs.

Continued in the report…..

Axial Spondyloarthritis (axSpA) Epidemiology  

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Axial Spondyloarthritis, Total Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis scenario in the United States from 2018 to 2030.


Key Findings

  • The total prevalent population of Axial Spondyloarthritis (axSpA) in the US was estimated to be 3,122,331 in 2020 which is anticipated to rise till 2030. Out of the total prevalent population, 1,336,050 cases were diagnosed in 2020.
  • In the epidemiology model, different age-groups are included, i.e., 18–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, and 70+ years. It is estimated that the most prevalent age-group for axSpA in the United States was 40–49 years in 2020.
  • The total prevalent population of nr-axSpA and AS in the US was estimated to be 1,821,360 and 1,300,971 in 2020, respectively.
  • In 2020, out of the total diagnosed cases of nr-axSpA, 670,252 cases had HLA-B27 gene mutation, and 109,111 cases involved other genes (ERAP 1, IL-12, IL-17, and IL-23). Additionally, in cases of AS, out of the total diagnosed cases in 2020, 501,019 cases involved HLA-B27 gene, and 55,669 cases had other genes involvement.
  • The prevalent population of AS showed a male predominance, whereas nr-axSpA showed a female predominance. Out of the total diagnosed population of nr-axSpA 779,363 cases in the US, 335,126 and 444,237 cases were contributed by males and females, respectively, in 2020.


“The diagnosis of axial spondyloarthritis (axSpA) can be tough to spot as so many people have back pain—its main symptom. Additionally, there are no specific lab tests to identify the condition. All these factors play a major role in the low diagnosis of axSpA. Gender difference in both the types of axSpA has shown different trend. In case of nr-axSpA, female dominance is observed, whereas in AS, male dominance is there.”

Axial Spondyloarthritis (axSpA) Epidemiology

The epidemiology segment also provides the axSpA epidemiology data and findings across the United States.

Axial Spondyloarthritis (axSpA) Drug Chapters


Axial Spondyloarthritis (axSpA) Marketed Drugs


Taltz (ixekizumab): Eli Lilly and Company

Taltz (ixekizumab) is the first humanized interleukin (IL)-17A antagonist therapy approved for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective inflammation signs. The therapy is now eligible to treat all types of axSpA including ankylosing spondylitis (AS), or radiographic axSpA, and nr-axSpA. It is a sterile, preservative-free, clear, and colourless to a slightly yellowish solution available as an auto-injector and prefilled syringe for subcutaneous administration. Both the injections contain a single dose of 80mg/ml solution of Taltz.

Products detail in the report…


Cosentyx: Novartis

Cosentyx (secukinumab) is a recombinant human monoclonal IgG1/κ antibody, which is developed by Novartis. This therapeutic molecule binds specifically to IL-17A cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. It also inhibits the release of pro-inflammatory cytokines and chemokines. This therapeutic molecule is indicated for the treatment of patients with Ankylosing Spondylitis, Psoriatic Arthritis, and Plaque Psoriasis.

Products detail in the report…


Humira (adalimumab): AbbVie

Humira (adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). It was created using phage display technology resulting in an antibody with human-derived heavy and light chain variable regions and human IgG1: k constant regions. It consists of 1,330 amino acids and has a molecular weight of approximately 148 kilodaltons. It binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. It also lyses surface TNF expressing cells in vitro in the presence of complement. Perhaps, it does not bind or inactivate lymphotoxin (TNF-beta). Adalimumab is approved in the United States, Europe, and Japan under the brand name “Humira” for the treatment of patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, and Crohn’s Disease. Cuurently, the drug is in phase III study for the treatment of non-radiographic axial spondyloarthritis.

Products detail in the report…

List to be continued in the report…


Axial Spondyloarthritis (axSpA) Emerging Drugs


Tofacitinib: Pfizer

Tofacitinib (CP-690,550) is a Janus kinase inhibitor. In the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs), which modulate intracellular activity, including gene expression. Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. The drug is approved in the US for four indications: adults with moderately to severely active rheumatoid arthritis (RA) after methotrexate failure, adults with active PsA after disease-modifying antirheumatic drug (DMARD) failure, adults with moderately to severely active ulcerative colitis (UC) after tumor necrosis factor inhibitor (TNFi) failure, and patients 2 years of age or older with active polyarticular course juvenile idiopathic arthritis (pcJIA).


The drug is not currently approved by the US Food and Drug Administration (FDA) to treat AS and is currently in Phase III clinical trial.

Products detail in the report…


Bimekizumab: UCB Biopharma

Bimekizumab (UCB4940) is the first humanized monoclonal IgG1 antibody that potently and selectively neutralizes IL-17A and IL-17F. These are the two key pro-inflammatory cytokines that share similar biological function and structural homology. IL-17A and IL-17F are the most closely related members of the IL-17 family of cytokines. They are both co-expressed at sites of inflammation and have overlapping pro-inflammatory functions. Both IL-17A and IL-17F can independently cooperate with other inflammatory mediators to drive chronic inflammation and tissue destruction. This therapeutic candidate is in the Phase III stage of development to treat patients with AS. The company is using the subcutaneous route of administration for AS, and non-radiographic axial spondyloarthritis.

Products detail in the report…


Rinvoq (Upadacitinib): AbbVie

Upadacitinib (ABT-494) is a second-generation JAK1 selective inhibitor currently under development by AbbVie for several inflammatory indications, such as AS. The Janus-kinases are a family of cytoplasmic tyrosine kinases which play an important role in transducing cytokine-mediated signals via the JAK-STAT pathway. Inhibitors of this enzyme family, such as upadacitinib, have shown conclusive evidence of efficacy in treating certain inflammatory and autoimmune disease conditions. The first generation of these enzyme inhibitors lacked subtype selectivity. However, their second generation has shown increased selectivity for the enzyme subtypes. This therapeutic candidate is in the Phase II stage of development for the treatment of patients with AS. On January 2021, the European Commission approved upadacitinib, to treat active psoriatic arthritis (PsA) in adults who have not adequately responded, or who are intolerant, to one or more disease-modifying anti-rheumatic drugs (DMARDs). It was also approved to treat active AS in adults for whom conventional therapy has proved inadequate.

Products detail in the report…

List to be continued in the report…

Axial Spondyloarthritis (axSpA) Market Outlook

Axial spondyloarthritis (axSpA) is a term that covers both patients with structural damage in the sacroiliac joints (SIJ) visible on X-rays, termed radiographic axSpA—r-axSpA (also known as ankylosing spondylitis/AS)—and patients who have not yet developed such structural damage in the SIJ, termed non-radiographic (nr)-axSpA. A substantial part of patients with axSpA will move from nr-axSpA to rad axSpA over time, but not all of them. The inflammation normally starts in the SIJ but can, later on, extend to inflammatory and structural changes in the spine. AxSpA is a disease of young people (starting before the age of 45 years, but often beginning in the third decade of life), and men are slightly more frequently affected than women.


A common treatment regimen for the various forms of spondyloarthritis (AS, psoriatic arthritis, enteropathic arthritis, reactive arthritis, juvenile spondyloarthritis, and undifferentiated spondyloarthritis) involves medication, exercise, physical therapy, good posture practices, and other options such as applying heat/cold to help relax muscles and reduce joint pain. In severe cases, posture correcting surgery may also be an option.


Depending on the type of spondyloarthritis, there may be some variation in treatment. For example, in psoriatic arthritis, both the skin component and joint component must be treated. In enteropathic arthritis (spondylitis/arthritis associated with inflammatory bowel disease), medications may need to be adjusted, so the gastrointestinal component of the disease is also treated and not exacerbated.


Treatment for axSpA usually starts with nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, and exercise. As long as the disease is not too advanced, NSAIDs and regular movement are usually enough to keep things under control. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as naproxen (Naprosyn) and indomethacin (Indocin and Tivorbex) are the medications preferred by doctors. They can relieve inflammation, pain, and stiffness. However, these medications might cause gastrointestinal bleeding. If NSAIDs are not helpful, the doctor might suggest starting a biologic medication, such as a tumor necrosis factor (TNF) blocker or an interleukin-17 (IL-17) inhibitor. Exercise or physical therapy is an integral part of any spondylitis program. Physical therapy is an important part of treatment and can provide several benefits, from pain relief to improved strength and flexibility. A physical therapist can design specific exercises for needs. Range-of-motion and stretching exercises can help maintain flexibility in the joints and preserve good posture. Proper sleeping and walking positions and abdominal and back exercises can help maintain upright posture. In recent years, many specialized diets have gained popularity among some people with arthritis.

Continued in the report…..


Key Findings

  • The market size of Axial Spondyloarthritis (axSpA) in the US is expected to increase in 2030 from USD 4,716 million in 2020, at a CAGR of 9.8% for the study period 2018–2030.
  • According to analysis, the current treatment market includes conventional therapies, biologics, and Cox Inhibitors.
  • The market size generated by Cox Inhibitors in 2020 was estimated to be USD 177 million, which by 2030 is expected to increase. Among all the US potential therapies, the highest market is expected to be captured by Bimekizumab.


“The total current market of axial spondyloarthritis is calculated based on the characterization of the current market: conventional therapies, biologics, and Cox Inhibitors. Certolizumab-pegol & Secukinumab are approved for axial spondyloarthritis, therefore it includes the market size of both nr-axSpA and AS. Whereas, Infliximab, adalimumab, etanercept, and golimumab are approved for only AS and hence they represent the market size of AS, but as per the KOL views and secondary search it is concluded that physicians are prescribing these therapies for the treatment of non-radiographic axial as well.


Among the pipeline candidates, i.e., Brodalumab (KHK4827, AMG 827), Bimekizumab, and Rinvoq (Upadacitinib) are expected to be used for both types of axSpA, i.e., AS and nr-axSpA. But Tofacitinib is in development for AS only. Due to targeting the large patient pool, Brodalumab, Bimekizumab, and Rinvoq, are estimated to generate a larger market size as compared to tofacitinib.”


The United States Market Outlook

This section provides the total axSpA market size and; market size by therapies in the United States.

Axial Spondyloarthritis (axSpA) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the axSpA market or expected to get launched in the market during the study period 2018–2030. The analysis covers the axSpA market uptake by drugs; patient uptake by therapies; and sales of each drug.  


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Axial Spondyloarthritis (axSpA) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for axSpA emerging therapies.

Reimbursement Scenario in Axial Spondyloarthritis (axSpA)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the axSpA market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability. 

Scope of the Report

  • The report covers the descriptive overview of axSpA, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the axSpA epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for axSpA is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the axSpA market; historical and forecasted is included in the report, covering the the United States drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the United States axSpA market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA, increasing incidence, effectiveness of drugs as both mono and combination therapy will positively drive the axSpA market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence axSpA R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for axSpA. The launch of emerging therapies will significantly impact the axSpA market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Axial Spondyloarthritis (axSpA) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • axSpA Pipeline Analysis
  • axSpA Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Axial Spondyloarthritis (axSpA) Report Key Strengths

  • 10 Years Forecast
  • United States Coverage
  • axSpA Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Axial Spondyloarthritis (axSpA) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the axSpA market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the axSpA total market size as well as market size by therapies across the Unites States during the forecast period (2021–2030)?
  • What are the key findings pertaining to the market across the United States and which country will have the largest axSpA market size during the forecast period (2021–2030)?
  • At what CAGR, the axSpA market is expected to grow at the United States level during the forecast period (2021–2030)?
  • What would be the axSpA market outlook across the United States during the forecast period (2021–2030)?
  • What would be the axSpA market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of axSpA?
  • What is the historical axSpA patient pool in the United States?
  • What would be the forecasted patient pool of axSpA in the United States level?
  • What will be the growth opportunities across the United States with respect to the patient population pertaining to axSpA ?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of axSpA during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the United states during the forecast period (2021–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of axSpA along with the approved therapy?
  • What are the current treatment guidelines for the treatment of axSpA in the US?
  • What are the axSpA marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of axSpA ?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of axSpA ?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the axSpA therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for axSpA and their status?
  • What are the key designations that have been granted for the emerging therapies for axSpA?
  • What are the United States historical and forecasted market of axSpA?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving axSpA.
  • To understand the future market competition in the axSpA market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for axSpA in the US.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the axSpA market.
  • To understand the future market competition in the axSpA market.

1. Key Insights

2. Report Introduction

3. Executive Summary of Axial Spondyloarthritis (axSpA)

4. Disease Background and Overview

4.1. Introduction

4.2. Cause

4.3. Etiology

4.3.1. Endogenous Factors

4.3.2. Exogenous Factors

4.4. Risk Factors

4.4.1. Gender

4.4.2. Family History

4.4.3. Genetic Predisposition

4.4.4. Age

4.5. Signs and symptoms

4.6. Genetics – an insight into the pathogenesis

4.6.1. HLAB27 causing AS

4.6.2. Antigen processing and presentation

4.6.3. IL-17 and type 3 immunity in AS

4.6.4. IL-17

4.6.5. IL-23 signaling

4.6.6. Targeting type-3 immunity in AS

4.7. Biomarkers

4.7.1. Genetic biomarkers

4.7.2. Markers for inflammation

4.7.3. Cartilage Turnover Markers

4.7.4. Other Biomarkers

4.8. Clinical Manifestations

4.8.1. Peripheral arthritis

4.8.2. Enthesitis

4.8.3. Restriction of spinal mobility

4.8.4. Hip and shoulder joints

4.8.5. Dactylitis

4.8.6. Extra-articular locations

4.9. Diagnosis

4.9.1. Blood tests

4.9.2. Imaging tests

4.10. Differential Diagnosis

4.11. Underdiagnoses and Diagnostic Delay

4.12. Diagnostic Criteria

4.13. New York Classification Criteria: Diagnostic Criteria for AS

5. Treatment and Management

5.1. Therapeutic treatment

5.1.1. Therapy

5.1.2. Surgery

5.1.3. Lifestyle and home remedies

5.2. Treatment Guidelines

5.2.1. ASAS-EULAR management recommendations for axial spondyloarthritis

5.2.2. Recommendations for the treatment of axial spondyloarthritis

5.2.3. APLAR axial spondyloarthritis treatment recommendations

6. Epidemiology and Patient Population

6.1. Methodology

6.2. United States

6.2.1. Assumptions and Rationale

6.2.2. Total Prevalent Cases of Axial Spondyloarthritis in the United States

6.2.3. Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States

6.2.4. Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States

6.2.5. Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States

6.2.6. Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States

7. Organizations contributing towards Axial Spondyloarthritis (AxSpA)

8. Patient Journey

9. Case Reports

10. Marketed Products

10.1. Key-cross Competition

10.2. Cimzia (Certolizumab pegol): UCB

10.2.1. Drug Description

10.2.2. Regulatory Milestones

10.2.3. Other Developmental Activities

10.2.4. Clinical Development

10.2.5. Safety and Efficacy

10.2.6. Product Profile

10.3. Humira (adalimumab): AbbVie

10.3.1. Drug Description

10.3.2. Regulatory Milestones

10.3.3. Other Developmental Activities

10.3.4. Clinical Development

10.3.5. Safety and Efficacy

10.3.6. Product Profile

10.4. Celebrex (celecoxib): Pfizer

10.4.1. Drug Description

10.4.2. Regulatory Milestones

10.4.3. Other Developmental Activities

10.4.4. Clinical Development

10.4.5. Safety and Efficacy

10.4.6. Product Profile

10.5. Enbrel (Etanercept): Amgen/Pfizer

10.5.1. Drug Description

10.5.2. Regulatory Milestones

10.5.3. Other Developmental Activities

10.5.4. Clinical Development

10.5.5. Safety and Efficacy

10.5.6. Product Profile

10.6. Remicade (Infliximab): Janssen Biotech

10.6.1. Drug Description

10.6.2. Regulatory Milestones

10.6.3. Other Developmental Activities

10.6.4. Clinical Development

10.6.5. Safety and Efficacy

10.6.6. Product Profile

10.7. Simponi (Golimumab): Janssen Biotech

10.7.1. Drug Description

10.7.2. Regulatory Milestones

10.7.3. Other Developmental Activities

10.7.4. Clinical Development

10.7.5. Safety and Efficacy

10.7.6. Product Profile

10.8. Vimovo (naproxen and esomeprazole magnesium): Pozen

10.8.1. Drug Description

10.8.2. Regulatory Milestones

10.8.3. Other Developmental Activities

10.8.4. Clinical Development

10.8.5. Safety and Efficacy

10.8.6. Product Profile

10.9. Cosentyx: Novartis

10.9.1. Drug Description

10.9.2. Regulatory Milestones

10.9.3. Other Developmental Activities

10.9.4. Clinical Development

10.9.5. Safety and Efficacy

10.9.6. Product Profile

10.10. Indocin: Iroko Pharmaceuticals

10.10.1. Drug Description

10.10.2. Safety and Efficacy

10.10.3. Product Profile

10.11. Naprelan: Syntex Pharmaceuticals

10.11.1. Drug Description

10.11.2. Other Developmental Activities

10.11.3. Product Profile

10.12. Rayos (Prednisone): Horizon Pharma

10.12.1. Drug Description

10.12.2. Regulatory Milestones

10.12.3. Other Developmental Activities

10.12.4. Product Profile

10.13. Taltz (ixekizumab): Eli Lilly and Company

10.13.1. Drug Description

10.13.2. Regulatory Milestones

10.13.3. Other Development Activities

10.13.4. Clinical Development

10.13.5. Safety and Efficacy

10.13.6. Product Profile

11. Emerging Therapies

11.1. Key Cross Competition

11.2. Tofacitinib: Pfizer

11.2.1. Product Description

11.2.2. Other Developmental Activities

11.2.3. Clinical Development

11.2.4. Safety and Efficacy

11.2.5. Product Profile

11.3. Bimekizumab: UCB Biopharma

11.3.1. Product Description

11.3.2. Other Developmental Activities

11.3.3. Clinical Development

11.3.4. Safety and Efficacy

11.3.5. Product Profile

11.4. Ilumya (Tildrakizumab): Sun Pharma Global

11.4.1. Product Description

11.4.2. Other Developmental Activities

11.4.3. Clinical Development

11.4.4. Product Profile

11.5. Namilumab: Izana Bioscience

11.5.1 Product Description

11.5.2. Other Developmental Activities

11.5.3. Clinical Development

11.5.4. Product Profile

11.6. ILT-101(Interleukin 2): Iltoo Pharma

11.6.1. Product Description

11.6.2. Other Developmental Activities

11.6.3. Clinical Development

11.6.4. Safety and Efficacy

11.6.5. Product Profile

11.7. Brodalumab (KHK4827): Kyowa Kirin

11.7.1. Product Description

11.7.2. Other Developmental Activities

11.7.3. Clinical Development

11.7.4. Safety and Efficacy

11.7.5. Product Profile

11.8. Rinvoq (Upadacitinib): AbbVie

11.8.1. Product Description

11.8.2. Other Developmental Activities

11.8.3. Clinical Development

11.8.4. Safety and Efficacy

11.8.5. Product Profile

11.9. Filgotinib: Galapagos/Gilead

11.9.1. Product Description

11.9.2. Other Developmental Activities

11.9.3. Clinical Development

11.9.4. Safety and Efficacy

11.9.5. Product Profile

12. Axial Spondyloarthritis (AxSpA): Market Analysis

12.1. Market Methodology

12.2. Attribute Analysis

12.3. Potential of Emerging Therapies and Current therapies

12.4. Key Market Forecast Assumptions

13. United States Market Outlook

13.1. United States Market Size

13.1.1. Total Market Size of Axial Spondyloarthritis in United States

13.1.2. Market Size of Axial Spondyloarthritis by Therapies in United States

14. Unmet Needs

15. Market Drivers

16. Market Barriers

17. SWOT Analysis

18. KOL Views

19. Access and Reimbursement Overview: Axial Spondyloarthritis (AxSpA)

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. DisclaimerList of

23. About DelveInsight

List of Table

Table 1: Summary of Axial Spondyloarthritis (AxSpA) Epidemiology, and Key Events (2018-2030)

Table 2: Summary of Axial Spondyloarthritis (AxSpA) Market, and Key Events (2018–2030)

Table 3: Confirmed and putative biomarkers for diagnosis, disease progression, and response to treatment in AS and axSpa

Table 4: Summary of the Differential Diagnosis of AxSpA

Table 5: Total Prevalent Cases of Axial Spondyloarthritis in the United States (2018−2030)

Table 6: Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2018-2030)

Table 7: Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2018-2030)

Table 8: Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2018-2030)

Table 9: Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2018-2030)

Table 10: Organizations contributing towards Axial Spondyloarthritis (AxSpA)

Table 11: Key cross competition- Marketed drugs

Table 12: Cimzia (certolizumab pegol), Clinical Trial Description, 2021

Table 13: Humira (adalimumab), Clinical Trial Description, 2021

Table 14: Celebrex (celecoxib), Clinical Trial Description, 2021

Table 15: Enbrel (Etanercept), Clinical Trial Description, 2021

Table 16: Remicade (Infliximab), Clinical Trial Description, 2021

Table 17: Simponi (Golimumab), Clinical Trial Description, 2021

Table 18: Vimovo (Esomeprazole/naproxen), Clinical Trial Description, 2021

Table 19: Cosentyx (secukinumab), Clinical Trial Description, 2021

Table 20: Taltz (ixekizumab), Clinical Trial Description, 2021

Table 21: Key cross competition of Emerging Therapies

Table 22: Tofacitinib, Clinical Trial Description, 2021

Table 23: Bimekizumab, Clinical Trial Description, 2021

Table 24: Tildrakizumab, Clinical Trial Description, 2021

Table 25: Namilumab, Clinical Trial Description, 2021

Table 26: ILT-101, Clinical Trial Description, 2021

Table 27: KHK4827, Clinical Trial Description, 2021

Table 28: Upadacitinib, Clinical Trial Description, 2021

Table 29: Filgotinib, Clinical Trial Description, 2021

Table 30: Key market forecast assumptions for Bimekizumab

Table 31: Key market forecast assumptions for Rinvoq

Table 32: Key market forecast assumptions for Brodalumab

Table 33: Key market forecast assumptions for Tofacitinib

Table 34: Key market forecast assumptions for Taltz

Table 35: United States Market Size of Axial Spondyloarthritis in USD Million (2018–2030)

Table 36: United States Market Size of Axial Spondyloarthritis by Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Pathology of entheses in AS

Figure 2: Risk Factors for AS

Figure 3: Functional roles of AS-associated genes

Figure 4: Antigen processing and presentation: a potential link to AS

Figure 5: Multiple roles for HLA-B27 in the pathogenesis of AS

Figure 6: Immune cells involved in the initiation, progression, and regulation of AS

Figure 7: The role of the gut in driving joint inflammation in AS

Figure 8: Potential mechanisms by which ERAP variants operate to influence disease risk in AS

Figure 9: Algorithm for the Diagnosis or Exclusion of AxSpA

Figure 10: ASAS classification criteria for axSpA

Figure 11: Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. ASDAS, Ankylosing Spondylitis Disease Activity Score

Figure 12: Recommendations for the treatment of axial spondyloarthritis

Figure 13: Total Prevalent Cases of Axial Spondyloarthritis in the United States (2018-2030)

Figure 14: Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2018-2030)

Figure 15: Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2018-2030)

Figure 16: Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2018-2030)

Figure 17: Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2018-2030)

Figure 18: Market Size of Axial Spondyloarthritis in the United States, USD Million (2018–2030)

Figure 19: The United States Market Size of Axial Spondyloarthritis by Therapies in USD Million (2018–2030)

Cimzia (Certolizumab pegol): UCB

Humira (adalimumab): AbbVie

Celebrex (celecoxib): Pfizer

Enbrel (Etanercept): Amgen/Pfizer

Remicade (Infliximab): Janssen Biotech

Simponi (Golimumab): Janssen Biotech

Vimovo (naproxen and esomeprazole magnesium): Pozen

Cosentyx: Novartis

Indocin: Iroko Pharmaceuticals

Naprelan: Syntex Pharmaceuticals

Rayos (Prednisone): Horizon Pharma

Taltz (ixekizumab): Eli Lilly and Company

Tofacitinib: Pfizer

Bimekizumab: UCB Biopharma

Ilumya (Tildrakizumab): Sun Pharma Global

Namilumab: Izana Bioscience

ILT-101(Interleukin 2): Iltoo Pharma

Brodalumab (KHK4827): Kyowa Kirin

Rinvoq (Upadacitinib): AbbVie

Filgotinib: Galapagos/Gilead

  • Tags:
  • Axial Spondyloarthritis (axSpA) mar...
  • Axial Spondyloarthritis (axSpA) ma...
  • Axial Spondyloarthritis (axSpA) ma...
  • Axial Spondyloarthritis (axSpA) ma...
  • Axial Spondyloarthritis (axSpA) ma...
  • Axial Spondyloarthritis (axSpA) ma...
  • Axial Spondyloarthritis (axSpA) pi...
  • Axial Spondyloarthritis (axSpA) tr...
  • Axial Spondyloarthritis (axSpA) dr...
  • Axial Spondyloarthritis (axSpA) sa...
  • Axial Spondyloarthritis (axSpA) ma...
  • Axial Spondyloarthritis (axSpA) di...
  • Axial Spondyloarthritis (axSpA) ep...
  • Axial Spondyloarthritis (axSpA)

Forward to Friend

Need A Quote